Cancer is a frightening prospect for a majority of people, but today several forms and types of cancer are fully treatable. Significantly, there are a large number of cancer survivors especially in developed countries. Research indicates that the death rate of cancer patients has reduced due the scientific advancement in cancer treatment including improvement in technology, detection/diagnostic equipment, as well as detection of abnormal cells before they turn into cancer cells.
Talking about early and efficient diagnosis, and treatment, NeoGenomics is a premier cancer diagnostics and pharma services company serving oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic and predictive testing. The company’s vision embodies uncompromising quality, exceptional service, and innovative solutions. It has a network of CAP-accredited, CLIA-certified facilities in the U.S., and offer global capabilities with laboratories in Switzerland and Singapore.
NeoGenomics has been serving the cancer community for over 17 years, and each member of its team is committed to its mission: Save lives by improving patient care.
Who We Are
NeoGenomics Laboratories is comprised of a national team of experts in developing and delivering laboratory diagnostic and clinical trial services with a focus in cancer. It is the common purpose of all NeoGenomics employees to save lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Its staff physicians, scientists, laboratory professionals, client services representatives, and sales people team up with our clients. Together, the company works to solve the medical, scientific, and logistical challenges of making precise diagnoses, aiding in bringing new therapies to market and finding the unique hallmarks of each patient’s disease that point the way to proper treatment.
What We Do
NeoGenomics provides expert bone marrow and surgical pathology consults; cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with one of the largest menu of technical-only services available; 10-color flow cytometry; histology supported by an extensive IHC antibody library; and >150 molecular oncology tests comprising the most comprehensive combination of multi-method tumor profiles and targeted biomarker tests in the industry. Its technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. Its Pharma Services division offers all of these methodologies along with other technology platforms to provide laboratory services that meet the rapidly evolving needs of its clients. Through our differentiators of expertise, flexibility and scalability it partners with its clients to develop better, more effective drugs.
It supports clients in many cancer-related market segments including hospital and private pathology laboratories, office-based oncologists, academic institutions, contract research and pharmaceutical development organizations, and more.
Why It Matters
People with cancer need more options, and it believes precision medicine is a critical component in controlling cancer. With all testing methodologies in one laboratory system, it has the ability to interrogate a blood-based cancer or solid tumor by as many means necessary to reveal biomarkers that expose that disease’s susceptibilities to standard or novel therapies. NeoGenomics’ extremely fast test development cycle means it is highly responsive to guideline changes and new therapy options. Design of our new tests always involves a balance of convention and innovation so costs are reduced and results become available promptly.
It all comes back to the patients. Time and results mean everything to its patients, and it keeps that first in its minds.
Meet the Expert
Douglas M. VanOort, Chairman of the Board of Directors and Chief Executive Officer: Mr. VanOort has served as the Chairman of the Board of Directors and Chief Executive Officer of NeoGenomics since October 28, 2009. For seven months prior to October 2009, he served as Chairman of the Board of Directors, Executive Chairman and Interim Chief Executive Officer. Prior to joining NeoGenomics, Mr. VanOort was a General Partner with a private equity firm, and a Founding Managing Partner of a venture capital firm. From 1982 through 1999, Mr. VanOort served in various positions at Corning Incorporated and at its spin-off company, Quest Diagnostics, Inc.
During the period from 1995 through 1999, he served as the Senior Vice President Operations for Quest Diagnostics, Inc. which was then a $1.5 billion newly formed NYSE-traded Company. During the period of 1989 to 1995, he held senior executive positions at Corning Life Sciences, Inc., including Executive Vice President. Corning Life Sciences Inc. had revenues of approximately $2 billion and was spun-off in a public transaction to create both Quest Diagnostics and Covance, Inc. From 1982 to 1989, Mr. VanOort served in various executive positions at Corning Incorporated, including Director of Mergers & Acquisitions. Mr. VanOort currently serves as a member of the Board of Directors of several privately-held companies, and is a principal owner of a privately-held retail hardware store chain. Mr. VanOort is a graduate of Bentley University.
“We are committed to improving patient care through innovative cancer testing that helps inform cancer diagnoses and therapeutic prediction for every cancer patient.”